

Date of Approval: November 13, 2008

# FREEDOM OF INFORMATION SUMMARY

## SUPPLEMENTAL NEW ANIMAL DRUG APPLICATION

NADA 013-076

TYLAN Soluble

Tylosin tartrate

Soluble powder

Swine

For the treatment and control of swine dysentery associated with *Brachyspira hyodysenteriae* when followed immediately by TYLAN Type A medicated article in feed.

For the control of porcine proliferative enteropathies (PPE, ileitis) associated with *Lawsonia intracellularis* when followed immediately by TYLAN Type A medicated article in feed.

Sponsored by:

Elanco Animal Health

**TABLE OF CONTENTS**

I. GENERAL INFORMATION:..... 1

II. EFFECTIVENESS:..... 2

    A. Dosage Characterization:..... 2

    B. Substantial Evidence:..... 2

III. TARGET ANIMAL SAFETY:..... 8

IV. HUMAN FOOD SAFETY: ..... 9

    A. Toxicology: ..... 9

    B. Residue Chemistry: ..... 9

    C. Microbial Food Safety: ..... 9

    D. Analytical Method for Residues: ..... 10

V. USER SAFETY: ..... 10

VI. AGENCY CONCLUSIONS:..... 10

    A. Marketing Status: ..... 10

    B. Exclusivity: ..... 10

    C. Supplemental Applications: ..... 11

    D. Patent Information: ..... 11

VII. ATTACHMENTS:..... 11

**I. GENERAL INFORMATION:**

- A. File Number:** NADA 013-076
- B. Sponsor:** Elanco Animal Health  
A Division of Eli Lilly & Co.  
Lilly Corporate Center  
Indianapolis, IN 46285
- Drug Labeler Code: 000986
- C. Proprietary Names:** TYLAN Soluble
- D. Established Name:** Tylosin tartrate
- E. Pharmacological Category:** Antimicrobial
- F. Dosage Forms:** Water soluble powder
- G. Amount of Active Ingredient:** 100 grams tylosin base per jar
- H. How Supplied:** Jars containing tylosin tartrate equivalent to 100 grams tylosin base
- I. How Dispensed:** OTC
- J. Dosage:** 250 mg tylosin per gallon in drinking water for 3 to 10 days, followed by 40 to 100 g tylosin per ton of complete feed (Type C medicated feed manufactured from TYLAN Type A medicated article) for 2 to 6 weeks.
- K. Routes of Administration:** Oral in water
- L. Species/Class:** Swine
- M. Indications:** For the treatment and control of swine dysentery associated with *Brachyspira hyodysenteriae* when followed immediately by TYLAN Type A medicated article in feed.
- For the control of porcine proliferative enteropathies (PPE, ileitis) associated with *Lawsonia intracellularis* when followed immediately by TYLAN

Type A medicated article in feed.

**N. Effect of Supplement:**

This supplement provides for the approval of TYLAN Soluble (tylosin tartrate) followed by TYLAN Type A medicated article (tylosin phosphate) for the treatment and control of swine dysentery associated with *Brachyspira hyodysenteriae* in swine and the control of porcine proliferative enteropathies (PPE, ileitis) associated with *Lawsonia intracellularis* in swine.

**II. EFFECTIVENESS:**

**A. Dosage Characterization:**

The dosage regimen tested for the control of porcine proliferative enteropathies (PPE, ileitis) was the currently approved dosage regimen for the use of tylosin in drinking water followed by tylosin in feed for the treatment and control of swine dysentery. This dosage regimen was selected because, while PPE and swine dysentery are caused by different pathogens, the two diseases share some clinical signs and are diagnosed under similar conditions. The effectiveness of tylosin in drinking water at 250 mg/gallon for 3 to 10 days followed by tylosin in feed at 40 to 100 grams per ton for 2 to 6 weeks for the treatment and control of swine dysentery was demonstrated for the approval of NADA 012-491 (TYLAN Type A medicated article) dated October 6, 1965 [30 FR 12730].

**B. Substantial Evidence:**

1. CVM did not require effectiveness studies for the supplemental approval of the indication for the treatment and control of swine dysentery associated with *Brachyspira hyodysenteriae* (when treatment with TYLAN Soluble is followed immediately by TYLAN Type A medicated article in feed). The supplemental approval of NADA 012-491 (TYLAN Type A medicated article) dated October 6, 1965 [30 FR 12730], contains a summary of studies that demonstrate effectiveness of this dosage regimen for the treatment and control of swine dysentery in pigs.

**2. Type of Study: Dose Confirmation Model Study**

- 1) **Title:** “An Efficacy Dose Confirmation Study with TYLAN Soluble Powder Followed by TYLAN Premix for the Control of Porcine Proliferative Enteropathy (ileitis) in Swine.” Study # T1XAM0501. January 2007 to March 2007.

2) Investigators and Locations:

Terry TerHune, DVM, PhD, HMS, Veterinary Development Inc.,  
Tulare, CA

Kelly Lechtenberg, DVM, PhD, Midwest Veterinary Services, Inc.,  
Oakland, NE

3) Study Design:

- a) *Objective:* To confirm the clinical effectiveness of tylosin tartrate administered in drinking water followed by tylosin phosphate, administered in a Type C medicated feed for the control of porcine proliferative enteropathies (PPE, ileitis) in swine. This study was conducted in accordance with CVM Guidance for Industry 85, “Good Clinical Practice” (VICH GL9) May 9, 2001.
- b) *Test Animals:* A total of 480 healthy, four to five week-old barrows and gilts were enrolled in this study. Pigs were obtained from separate swine sources for each study site. Animals weighed 11.4 to 28.6 pounds at enrollment, and originated from herds demonstrated to be free of *Lawsonia intracellularis* by polymerase chain reaction testing of random fecal samples prior to purchase.
- c) *Experimental Design:* The study was conducted at two independent sites. A randomized complete block design was used at each site. The pen was the experimental unit. Treatment and control animals were not commingled in pens. Pens contained six pigs at the beginning of the study and there were 20 pens enrolled at each site.

On Day 0, all pigs were challenged with intestinal mucosal homogenate prepared from sections of affected pig intestine which were obtained from a recent, North American case of PPE. Pigs were dosed by gastric gavage to inoculate each pig with approximately  $10^9$  *Lawsonia intracellularis* organisms.

- d) *Treatment Groups:* On Day -7, animals were ranked by descending weight within gender and randomly assigned to pens. Pens were then randomly assigned to treatment group (Table 1).

**Table 1. Treatment Groups**

<b>Group</b>	<b>Test Article</b>	<b>Dose/Route</b>	<b>Frequency/Duration</b>
Treated	Tylosin tartrate	250 mg tylosin/gallon of drinking water	<i>Ad libitum</i> for three days
	<b>Followed by:</b> Tylosin phosphate	40 g tylosin/ton in feed	<i>Ad libitum</i> for 14 days
Negative Control	Non-medicated water	0	<i>Ad libitum</i> for three days
	<b>Followed by:</b> Non-medicated feed	0	<i>Ad libitum</i> for 14 days

- e) *Test Article Administration:* Tylosin as the tartrate salt (TYLAN Soluble) was administered in the drinking water at 250 mg tylosin/gallon (65.8 ppm) for three days followed by tylosin as the phosphate salt (TYLAN Type A medicated article) administered in feed containing 40 g tylosin/ton for 14 days. Day X was defined as the day that 15% of the total population of study pigs at the study site were observed to be clinically affected with PPE in a single day. A pig was considered clinically affected when it had a diarrhea score of 2 or 3 (see score definitions below). Tylosin was administered in the drinking water from Day X + 1 through Day X + 3 and tylosin was administered in the feed from Day X + 4 through Day X + 17. Control pigs received no medication in water or feed for the duration of the study.

On Day X, four clinically affected pigs at each site were randomly selected for necropsy and areas of affected intestine were tested for *L. intracellularis* by immunohistochemical (IHC) stain to confirm the presence of PPE in study animals. Not more than one pig was removed from an individual pen for this test.

- f) *Measurements and Observations:* Pigs were observed twice daily. Animal health observations included observations for survival, general condition, and any abnormal clinical signs.

The primary variables were the percent abnormal pig days for each clinical score (diarrhea, abdominal gut fill, and pig attitude), mortality, lesion index, and average daily gain (ADG).

Clinical scores were evaluated daily from Day X + 1 through Day X + 17.

Diarrhea was described using the following clinical scoring scale.

- 1 = Normal, no diarrhea – Feces are formed with no evidence of abnormal consistency.  
 2 = Semi-loose – Feces are soft: examples include

- “oatmeal” or “cow-pie” consistency. Fecal material will “pile or puddle” on the pen floor.
- 3 = Watery diarrhea – Feces are watery, containing primarily fluid versus solid material, readily running off the slatted floor.

Abdominal gut fill was described using the following clinical scoring scale.

- 1 = Normal – Flank is full and rounded.  
2 = Moderately gaunt – Flank is flat.  
3 = Severely gaunt – Flank is very hollow.

Pig attitude was described using the following clinical scoring scale.

- 1 = Normal – Animal is bright, alert, and active, responding to stimuli.  
2 = Slightly to moderately depressed or listless – Animal slowly responds to stimuli, but may keep head/ears lowered.  
3 = Severely depressed or recumbent – Animal may slowly respond to stimuli briefly, but prefers to lie back down quickly. Remains isolated from group.

The percent abnormal pig days for each clinical score was calculated for each pen by summing the total number of days with an abnormal score (Score = 2 or Score = 3) for all pigs in a pen and dividing this numerator by the sum of all study days for which each pig was alive, across all pigs in each pen.

Pigs that died or were euthanized from Day X + 1 through Day X+17 were weighed, necropsied, and considered “mortalities associated with PPE” if they had intestinal lesions consistent with PPE at necropsy (see scoring scale below).

On Day X + 18, all remaining pigs were weighed, euthanized, necropsied, and scored for PPE lesions according to the following criteria:

- 1 = Normal; no gross lesions  
2 = Mild mesoserosal edema and hyperemia; a mild PPE lesion  
3 = Edema, hyperemia, reticulated serosa and thickened mucosa; a moderate PPE lesion  
4 = Edema, hyperemia, reticulated serosa and mucosa, very gross thickening of the mucosa, blood or

fibrin; a severe PPE lesion and/or necrotic enteritis

The lesion index was defined as the sum of the lesion score multiplied by the associated lesion length:

$$\text{Lesion Index} = \sum (i \times l_i),$$

where  $i = 2, 3, 4$  (lesion score)  
and  $l_i = \text{length (cm) associated with lesion score } i$ .

Individual pig body weights (BW) by pen were recorded on Days -7, Day X, and X + 18. ADG was calculated for each pen by averaging the individual pigs' average daily gains within the pen. ADG for each individual pig was calculated by subtracting the study animal's weight on Day X from that same weight on Day X + 18 and dividing the result by 18.

At least one of the following sets of criteria had to be met in order to demonstrate effectiveness:

- At least two of the three clinical parameters were statistically significantly improved ( $p \leq 0.05$ ) in the treated group compared to the control group – AND – Mortality was not statistically significantly higher ( $p \leq 0.05$ ) in the treated group compared to the control group.

**OR**

- The lesion index was statistically significantly improved ( $p \leq 0.05$ ) in the treated group compared to the control group – AND – Average daily gain (ADG) was numerically higher in the treated group compared to the control group – AND – Mortality was not statistically significantly higher ( $p \leq 0.05$ ) in the treated group compared to the control group.

g) *Statistical Analysis:* The criteria for substantial evidence of effectiveness required demonstration of effectiveness at each site, analyzed separately. For each of the clinical parameters (diarrhea score, abdominal gut fill score, pig attitude score) arcsine square root transformed percent of pig-days with abnormal scores (Score = 2 or Score = 3) was analyzed using a mixed effect linear model with treatment as a fixed effect and with block and residual as random effects. A one-sided comparison of tylosin versus negative control was conducted at the 0.05 significance level, with lower percent abnormal among treated groups considered favorable.

Percent mortality was compared between the two treatment groups using Fisher's Exact Test at the 0.05 level of significance.



4) **Results:** A total of 470 pigs completed the study.

- a) *Clinical Scores:* At Site 1, abnormal pig days for gut fill was significantly improved in the treated group compared to the control group ( $p = 0.0034$ ), and abnormal pig days for diarrhea was significantly improved in the treated group compared to the control group ( $p = 0.0017$ ). Similarly, at Site 2, abnormal pig days for gut fill was significantly improved in the treated group compared to the control group ( $p < 0.0001$ ), and abnormal pig days for diarrhea was significantly improved in the treated group compared to the control group ( $p = 0.0001$ ). Significant differences in percent abnormal pig days for attitude were seen between control and treated groups at Site 1 ( $p = 0.0011$ ) but not at Site 2 ( $p = 0.2067$ ).

**Table 2. Percent Abnormal Pig-Days for Clinical Parameters<sup>1</sup>**

Site	Treatment Group	Diarrhea <sup>2</sup> (%)	Pig Attitude <sup>2</sup> (%)	Gut Fill <sup>2</sup> (%)
1	Tylosin	77.9 <sup>a</sup>	8.1 <sup>a</sup>	12.9 <sup>a</sup>
	Control	90.7 <sup>b</sup>	17.8 <sup>b</sup>	20.5 <sup>b</sup>
2	Tylosin	40.0 <sup>a</sup>	2.3 <sup>a</sup>	47.2 <sup>a</sup>
	Control	56.7 <sup>b</sup>	3.3 <sup>a</sup>	69.3 <sup>b</sup>

<sup>1</sup> Within each column at a given site, values with different superscripts indicate statistically significant differences between treatment and control groups ( $p \leq 0.05$ ).

<sup>2</sup> Values are back-transformed from LSM means.

- b) *Mortality:* At each site, no significant increase in mortality was observed in the tylosin-treated group. At Site 1, percent mortality was 10.3% for control animals and 3.3% for tylosin-treated animals. At Site 2, percent mortality was 0% for both control and tylosin-treated animals.
- c) *Lesion Index:* The lesion index for each pig was calculated as the sum of the lesion score multiplied by the associated lesion length. The average pen lesion index was then computed. Examination of the standard errors versus the means justified the use of the LOG+1 transformation. The lesion index differed significantly between control and tylosin-treated animals at Site 1 ( $p < 0.0001$ ) but not at Site 2 ( $p = 0.0549$ ). At Site 1, the back-transformed mean lesion index was numerically less in tylosin-treated animals (73) than in control animals (237). At Site 2, however, the back-transformed mean lesion index was numerically greater in tylosin-treated animals (180) than in control animals (122).
- d) *ADG:* ADG was computed for each individual pig, and averaged across all pigs within a pen. At Site 1, ADG differed significantly ( $p = 0.0007$ ) between tylosin-treated pens (0.25 kg/day) and control pens (0.19 kg/day). At Site 2, ADG was not significantly different ( $p = 0.5156$ ) in the

tylosin-treated pens (0.35 kg/day) compared to the control pens (0.33 kg/day).

- e) *Secondary Variables*: Mean average daily feed intake (ADFI), mean feed to gain ratio (F/G), and mean pen total BW gain were examined at each site (Table 3). At Site 1, ADFI did not significantly change ( $p = 0.1497$ ) in the tylosin-treated pens (0.59 kg feed/day) compared to the control pens (0.57 kg feed/day), F/G significantly decreased ( $p = 0.0002$ ) in the tylosin-treated pens (2.46) compared to the control pens (3.43), and pen total BW gain significantly increased ( $p < 0.0001$ ) in the tylosin-treated pens (27.3 kg) compared to the control pens (18.9 kg). At Site 2, ADFI did not significantly increase ( $p = 0.4334$ ) in the tylosin-treated pens (0.64 kg/day) compared to the control pens (0.65 kg/day), F/G did not significantly decrease ( $p = 0.1145$ ) in the tylosin-treated pens (1.89) compared to the control pens (1.97), and pen total BW gain did not significantly increase ( $p = 0.4948$ ) in the tylosin-treated pens (35.8 kg) compared to the control pens (35.8 kg).

**Table 3. Secondary Variables<sup>1</sup>**

Site	Treatment Group	Average Daily Feed Intake (kg/day) <sup>2</sup>	Feed/Gain <sup>2</sup>	Pen Total Weight Gain (kg) <sup>2</sup>
1	Tylosin	0.59 <sup>a</sup>	2.46 <sup>a</sup>	27.3 <sup>a</sup>
	Control	0.57 <sup>a</sup>	3.43 <sup>b</sup>	18.9 <sup>b</sup>
2	Tylosin	0.64 <sup>a</sup>	1.89 <sup>a</sup>	35.8 <sup>a</sup>
	Control	0.65 <sup>a</sup>	1.97 <sup>a</sup>	35.8 <sup>a</sup>

<sup>1</sup>Values with different superscripts within each column are statistically significant ( $p \leq 0.05$ ).

<sup>2</sup>Values are LSM means.

- 5) Adverse Reactions: No adverse reactions attributable to the test article were reported at either site.
- 6) Conclusions: Treated animals had statistically significant improvement in two of the three clinical parameters (abnormal pig days for gut fill and abnormal pig days for diarrhea) and mortality was not statistically significantly higher in the treated group compared to the control group. This study demonstrated that the use of tylosin tartrate, administered in drinking water at 250 mg tylosin/gallon (65.8 ppm) for three days followed by tylosin phosphate administered at 40 g tylosin/ton in feed for two weeks, was effective for the control of PPE (ileitis) in swine.

### III. TARGET ANIMAL SAFETY:

CVM did not require target animal safety studies for this supplemental approval. Target animal safety for the use of TYLAN Soluble in swine at 250 mg tylosin per gallon of

drinking water for 3 to 10 days was demonstrated for the approval of NADA 013-076 dated April 5, 1962.

#### **IV. HUMAN FOOD SAFETY:**

##### **A. Toxicology:**

CVM did not require toxicology studies for this supplemental approval. The original approval of NADA 012-491 as published in the FEDERAL REGISTER [26 FR 4369] on May 19, 1961, contains summaries of all toxicology studies.

##### **B. Residue Chemistry:**

###### **1. Summary of Residue Chemistry Studies**

CVM did not require residue chemistry studies for this supplemental approval. The original approval of NADA 012-491 as published in the FEDERAL REGISTER [26 FR 4369] on May 19, 1961, contains a summary of residue chemistry studies for swine.

###### **2. Target Tissue and Marker Residue Assignment**

No marker residue or target tissue is specified for tylosin.

###### **3. Tolerance Assignments**

As described in CFR 556.740, a tolerance of 0.2 parts per million (negligible residue) is established for residues of tylosin in the uncooked edible tissues of swine.

###### **4. Withdrawal Time**

The product qualifies for a zero-day withdrawal period.

##### **C. Microbial Food Safety:**

The Agency carefully considered the additional label indications, "for treatment and control of swine dysentery associated with *Brachyspira hyodysenteriae*," and "for control of porcine proliferative enteropathies (PPE, ileitis) associated with *Lawsonia intracellularis*," for tylosin administered at 250 mg/gal in drinking water for 3 to 10 days, followed by 40 to 100 g/ton tylosin in feed for 2 to 6 weeks in swine. The Agency determined that the additional indications should not significantly impact public health, and therefore an evaluation of microbial food safety was not necessary at this time.

**D. Analytical Method for Residues:**

The original approval of NADA 012-491 as published in the FEDERAL REGISTER [26 FR 4369] on May 19, 1961, contains the analytical method summaries for tylosin in swine.

**V. USER SAFETY:**

The product labeling contains the following information regarding safety to humans handling, administering, or exposed to TYLAN Soluble:

When directed to mix the product with water, always add the water to the powder. Do not pour the powder into the water. Prepare a fresh TYLAN Solution every three days. When mixing and handling tylosin, use protective clothing and impervious gloves.

Avoid contact with human skin. Exposure to tylosin may cause a rash.

Not for human use.

To report adverse effects, access medical information, or obtain additional product information, call 1-800-428-4441.

**VI. AGENCY CONCLUSIONS:**

The data submitted in support of this NADA satisfy the requirements of section 512 of the Federal Food, Drug, and Cosmetic Act and 21 CFR part 514. The data demonstrate that TYLAN Soluble, when used according to the label, is safe and effective for the treatment and control of swine dysentery associated with *Brachyspira hyodysenteriae* and for the control of porcine proliferative enteropathies (PPE, ileitis) associated with *Lawsonia intracellularis* in swine when followed immediately by TYLAN Type A medicated article in feed. Additionally, data demonstrate that residues in food products derived from swine treated with TYLAN Soluble will not represent a public health concern when the product is used according to the label.

**A. Marketing Status:**

This product can be marketed over-the-counter (OTC) because the approved labeling contains adequate directions for use by laypersons and the conditions of use prescribed on the label are reasonably certain to be followed in practice.

**B. Exclusivity:**

Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act, this approval qualifies for THREE years of marketing exclusivity beginning on the date of the approval. The three years of marketing exclusivity applies only to the new claim for the control of porcine proliferative enteropathies (PPE, ileitis) associated

with *Lawsonia intracellularis* when followed immediately by TYLAN Type A medicated article in feed for which this supplement is approved.

**C. Supplemental Applications:**

This supplemental NADA did not require a reevaluation of the safety or effectiveness data in the original NADA (21 CFR 514.106(b)(1)).

**D. Patent Information:**

The sponsor did not submit any patent information with this application.

**VII. ATTACHMENTS:**

Facsimile Labeling:

TYLAN Soluble – 100 g jar; English-only jar label

TYLAN Soluble – 100 g jar; English/Spanish jar label